Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications
暂无分享,去创建一个
Fan Zhou | J. Hou | Wei Wei | Wenjun Yu | Hao-tian Shi | Nian Zhou | Haimin Chen | Lixia Wu | R. Peng | Wenhao Zhao
[1] A. Tafuri,et al. Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group , 2022, EJHaem.
[2] S. Srinivasan,et al. Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients , 2020, Cancer medicine.
[3] P. Liu,et al. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study , 2020, Annals of Hematology.
[4] A. Laganà,et al. A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma , 2020, Leukemia & lymphoma.
[5] M. Beksac,et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study , 2019, The Lancet.
[6] F. Patriarca. Frontline therapy in multiple myeloma: fast start for a long game. , 2019, The Lancet. Haematology.
[7] E. Esin,et al. Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience , 2019, Journal of oncology.
[8] D. Hughes,et al. Bortezomib consolidation post‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse , 2018, British journal of haematology.
[9] R. Raymakers,et al. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients , 2018, British journal of haematology.
[10] C. Murray,et al. On the road to universal health care in Indonesia, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet.
[11] C. Fitzmaurice,et al. Global burden of multiple myeloma: A systematic analysis for the Global Burden of Disease study 2016. , 2018 .
[12] M. Naghavi,et al. Global Burden of Multiple Myeloma , 2018, JAMA oncology.
[13] M. Dimopoulos,et al. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Sibel Naycı,et al. The View of the Turkish Thoracic Society on the Report of the GOLD 2017 Global Strategy for the Diagnosis, Management, and Prevention of COPD. , 2017, Turkish thoracic journal.
[15] A. Salihoglu,et al. Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors , 2017, Turkish journal of haematology : official journal of Turkish Society of Haematology.
[16] D. Kazandjian. Multiple myeloma epidemiology and survival: A unique malignancy. , 2016, Seminars in oncology.
[17] S. Lonial,et al. Integration of Novel Agents into the Care of Patients with Multiple Myeloma , 2016, Clinical Cancer Research.
[18] P. Sonneveld,et al. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. , 2016, Blood.
[19] H. Goldschmidt,et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.
[20] E. Vellenga,et al. Combination therapy with bortezomib, continuous low‐dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients , 2015, British journal of haematology.
[21] Fan Zhou,et al. 持续口服小剂量环磷酰胺联合泼尼松治疗复发/难治性多发性骨髓瘤伴严重心功能不全患者疗效观察 , 2015, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.
[22] Fan Zhou,et al. Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure , 2014, Leukemia & lymphoma.
[23] I. Manițiu,et al. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP) , 2013, Cardiovascular journal of Africa.
[24] H. Goldschmidt,et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.
[25] J. Leonard,et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma , 2010, Cancer.
[26] Robert A Kyle,et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.
[27] Fan Zhou,et al. Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma. , 2009, Clinical lymphoma, myeloma & leukemia.
[28] G. Koren,et al. A Pilot Pharmacokinetic and Antiangiogenic Biomarker Study of Celecoxib and Low-dose Metronomic Vinblastine or Cyclophosphamide in Pediatric Recurrent Solid Tumors , 2006, Journal of pediatric hematology/oncology.
[29] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[30] A. Hagenbeek,et al. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. , 2001, The Netherlands journal of medicine.
[31] Gabriele Bergers,et al. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.
[32] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[33] P. L. Bergsagel,et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. , 2013, Mayo Clinic proceedings.
[34] H. Goldschmidt,et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.